The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.

Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.